Inmune Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Moss David J, was filed 30 Sept 2024.
Inmune Bio, Inc.: what insiders have been doing
Inmune Bio, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 3 insiders have disclosed 3 filings since 22 October 2025.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 3 filings, this issuer sits below that mark. Over the whole record (from 2019), the tally stands at 35 purchases and 23 sales. The 10-K for the year ended 31 December 2025 shows 50,000 USD of revenue and -45.9 m USD of net income.
No insider has bought Inmune Bio, Inc. shares on the open market in the past twelve months. Typically, a trade is published a median of 5 days after it takes place. Section 16 rules allow two business days to file each Form 4.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Since the insiders bought
- -61.3%Entry US$5.51 · Close at T+365 US$2.13
- -65.6%Entry US$5.55 · Close at T+365 US$1.91
- -38.7%Entry US$8.69 · Close at T+365 US$5.33
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 9,014 shares@ US$1.400.022% mcap1.5% of flowCommon StockSEC:0001213900-26-075736:0
- 14,801 shares@ US$1.400.037% mcap5.1% of flowCommon StockSEC:0001213900-26-075738:0
- 7,211 shares@ US$1.400.018% mcap1.9% of flowCommon StockSEC:0001213900-26-075737:0
- 10,000 shares@ US$5.28686.4% of flowCommon StockSEC:0001213900-24-083348:0Canonical exit: 29 Dec 2024 (T+90)
- 7,690 shares@ US$6.3756.0% of flowCommon StockSEC:0001213900-24-079119:0Canonical exit: 11 Dec 2024 (T+90)
- 15,380 shares@ US$6.3757.2% of flowCommon StockSEC:0001213900-24-079121:0Canonical exit: 11 Dec 2024 (T+90)
- 5,000 shares@ US$7.279.5% of flowCommon StockSEC:0001213900-24-055920:0Canonical exit: 23 Sept 2024 (T+90)
- 29,603 shares@ US$8.3264.5% of flowCommon StockSEC:0001213900-24-035471:0
- 18,028 shares@ US$8.3211.5% of flowCommon StockSEC:0001213900-24-035474:0
- 18,028 shares@ US$8.3219.0% of flowCommon StockSEC:0001213900-24-035473:0
- 14,423 shares@ US$8.3224.5% of flowCommon StockSEC:0001213900-24-035472:0
- 7,000 shares@ US$6.9512.7% of flowCommon StockSEC:0001213900-23-085758:0Canonical exit: 8 Feb 2024 (T+90)
- 10,000 shares@ US$11.00857.5% of flowCommon StockSEC:0001213900-23-057083:0
- 2,500 shares@ US$6.4252.0% of flowCommon StockSEC:0001213900-23-021235:0Canonical exit: 15 Jun 2023 (T+90)
- 3,000 shares@ US$6.791.6% of flowCommon StockSEC:0001213900-22-030208:1Canonical exit: 25 Aug 2022 (T+90)
- 6,300 shares@ US$6.413.1% of flowCommon StockSEC:0001213900-22-030210:0Canonical exit: 24 Aug 2022 (T+90)
- 7,700 shares@ US$6.276.1% of flowCommon StockSEC:0001213900-22-030208:0Canonical exit: 24 Aug 2022 (T+90)
- 23,590 shares@ US$8.4339.2% of flowCommon StockSEC:0001213900-22-014509:0
- 17,793 shares@ US$8.43100.0% of flowCommon StockSEC:0001213900-22-014499:0
- 23,724 shares@ US$8.4314.8% of flowCommon StockSEC:0001213900-22-014507:0
- 17,793 shares@ US$8.4318.3% of flowCommon StockSEC:0001213900-22-014504:0
- 2,500 shares@ US$13.558.3% of flowCommon StockSEC:0001213900-21-060386:0Canonical exit: 15 Feb 2022 (T+90)
- 1,025 shares@ US$20.002.4% of flowCommon StockSEC:0001213900-21-056738:0
- 3,626 shares@ US$20.005.1% of flowCommon StockSEC:0001213900-21-056737:0
- 701 shares@ US$20.002.6% of flowCommon StockSEC:0001213900-21-056740:0
25 of 74 declarations
About Inmune Bio, Inc.
INmune Bio, Inc. is a US-listed clinical-stage biotechnology company trading on the NASDAQ under the ticker INMB. Headquartered in Boca Raton, Florida, United States, the company is focused on developing immunotherapies that reprogram the innate immune system, with a precision-medicine approach aimed at serious inflammatory and immune-mediated diseases with high unmet medical need. The company was founded in 2015 and was built around the concept of harnessing the body’s innate immune response rather than simply suppressing disease symptoms. ([inmunebio.com](https://www.inmunebio.com/index.php/about-us?utm_source=openai))
INmune Bio originally emerged as an immuno-oncology story and has since expanded into neuroinflammation and rare inflammatory disorders. Its main programs include INKmune, designed to activate NK-cell function in certain hematologic malignancies and solid tumors; INB03, another oncology-oriented asset; and XPro1595, a candidate targeting soluble TNF that has been studied in Alzheimer’s disease and other neuroinflammatory settings. More recently, the company has also highlighted CORDStrom for recessive dystrophic epidermolysis bullosa (RDEB), showing that its platform is being extended beyond oncology and neurology into rare disease biology. ([inmunebio.com](https://www.inmunebio.com/index.php/about-us?utm_source=openai))
Read moreShow less
From a competitive standpoint, INmune Bio operates in one of the most challenging corners of biotech: clinical-stage development with high cash burn, binary trial outcomes, and strong dependence on regulatory milestones. Its differentiating factor is scientific focus. By targeting innate immunity, the company is positioned differently from many peers that rely more heavily on adaptive immune or broad anti-inflammatory mechanisms. For investors, the name should therefore be viewed as a pipeline-driven biotech story rather than a mature commercial business, with valuation likely to remain highly sensitive to clinical readouts, financing conditions, and regulatory progress. ([inmunebio.com](https://www.inmunebio.com/index.php/about-us?utm_source=openai))
Geographically, INmune Bio is based in Boca Raton, Florida, United States, and also maintains operational capabilities in the United Kingdom through a local manufacturing space lease and related subsidiary activity. That transatlantic footprint reflects the global nature of its clinical and manufacturing strategy. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/ea0279078-10k_inmune.htm?utm_source=openai))
Recent developments have been centered on 2025 and 2026 business updates. The company reported clinical progress for MINDFuL in Alzheimer’s disease, continued advancement of CORDStrom, and ongoing evaluation of INKmune in prostate cancer. These updates reinforce the picture of a late-stage clinical biotech with meaningful scientific optionality, but also with substantial execution risk, which is typical for small-cap NASDAQ-listed biotech companies in the United States. ([nasdaq.com](https://www.nasdaq.com/press-release/inmune-bio-inc-announces-second-quarter-2025-results-provides-business-update-and?utm_source=openai))
